Basel, Switzerland (UroToday.com) Dr. Bertrand Tombal discussed antiresorptive therapy to reduce SRE risk for the majority of men with CRPC and bone metastases as part of the debate regarding how aggressive to be with bone-targeted therapy at the Advanced Prostate Cancer Consensus Conference (APCCC) 19 biennial meeting. Dr. Tombal explains that the concept of skeletal-related events […]
Basel, Switzerland (UroToday.com) Dr. William Oh discussed the use of androgen deprivation therapy (ADT) alone vs. the use of ADT in addition to one of the available systemic therapies in metastatic prostate cancer. From the 1990s the death rate from prostate cancer has been gradually declining. Death from prostate cancer usually occurs when it is in […]
Basel, Switzerland (UroToday.com) At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 Drs. Maha Hussain and Celestia Higano presented during the management of castration-resistant prostate cancer (CRPC) debate. Each clinician presented on one side of comparison regarding the treatment of non-metastatic (nmCRPC). Dr. Maha Hussain presented the “pros” of treating men with nmCRPC. Until early 2018, nmCRPC was […]
Basel, Switzerland (UroToday.com) At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 Drs. Maha Hussain and Celestia Higano presented during the management of castration-resistant prostate cancer (CRPC) debate. Each clinician presented on one side of comparison regarding the treatment of non-metastatic (nmCRPC). Dr. Higano presented on the “cons” of treating men with nmCRPC. The standard definition of […]
Basel, Switzerland (UroToday.com) Dr. Ian Davis briefly showed some of the progress that has been made with the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer. This registry also includes molecular subtyping and patient-reported outcome measures (PROMs). The ultimate goal of this project is to provide the most elaborate description and understanding of […]
Basel, Switzerland (UroToday.com) Medical oncologist Eleni Efstathiou provided an overview of neuroendocrine prostate cancer during the management of CRPC session at the APCCC 2019 meeting. Dr. Efstathiou notes that the original definition of neuroendocrine prostate cancer was as follows: tumors that during the course of androgen deprivation become less dependent on androgen signaling and have invariably […]
It has consistently been shown that women who are diagnosed with bladder cancer have lower survival than men, but the exact mechanism remains unknown. Most studies assumed that the sex-specific mortality ratio is constant over time, possibly resulting in inaccurate estimates in various periods of follow-up. This study aimed to investigate the sex-specific excess mortality […]
Basel, Switzerland (UroToday.com) As part of the management of CRPC session at APCCC 2019, Susan Halabi discussed the implications of subgroup analyses in mCRPC trials. Dr. Halabi started by making it clear that in large clinical trials a hypothesis tested usually addresses an overall or average treatment effect in the study population, and there is no […]
Basel, Switzerland (UroToday.com) Patient advocate, and 20+ year prostate cancer survivor Robin Millman provided the patient’s perspective for the future of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 biennial meeting. Wish #1: General Population ScreeningMr. Millman notes that it is important for both physicians and patients to raise public awareness and […]
Basel, Switzerland (UroToday.com) To start off the session on management of castration-resistant prostate cancer (CRPC) at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) meeting, Dr.Howard Scher from the Memorial Sloan Kettering Cancer Center gave an overview of non-metastatic CRPC (nmCRPC), those who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan […]
